BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/28/2020 10:31:57 AM | Browse: 926 | Download: 1441
 |
Received |
|
2019-10-31 12:45 |
|
Peer-Review Started |
|
2019-10-31 12:46 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-12-04 22:18 |
|
Revised |
|
2020-01-03 13:07 |
|
Second Decision |
|
2020-01-18 07:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-01-28 18:01 |
|
Articles in Press |
|
2020-01-28 18:01 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-02-18 02:29 |
|
Publish the Manuscript Online |
|
2020-02-28 10:31 |
| ISSN |
1948-9358 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Cassandra Spanos, Ingrid Bretherton, Jeffrey D Zajac and Ada S Cheung |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Australian Government National Health and Medical Research Council |
APP1143333 |
| Endocrine Society of Australia |
|
| Austin Medical Research Foundation |
|
| Viertel Charitable Foundation Clinical Investigator Award |
VIERCI2017009 |
| Royal Australasian College of Physicians Vincent Fairfax Family Foundation |
|
|
| Corresponding Author |
Ada S Cheung, FRACP, MBBS, MD, PhD, Doctor, Doctor, Senior Research Fellow, Department of Medicine (Austin Health), Australia; Department of Endocrinology, The University of Melbourne, 145 Studley Road, Heidelberg 3084, Victoria, Australia. adac@unimelb.edu.au |
| Key Words |
Transgender persons; Insulin resistance; Body composition; Gender dysphoria; Metabolic syndrome; |
| Core Tip |
Evidence in transgender men suggests that testosterone therapy increases lean mass, decreases fat mass and has no impact on insulin resistance. Evidence in transgender women suggests that feminising hormone therapy (estradiol, with or without anti-androgen agents) decreases lean mass, increases fat mass, and may worsen insulin resistance. There is a paucity of prospective controlled research, and existing prospective evidence is limited by small sample sizes, short follow up periods, and young cohorts of participants. Until further evidence is available, clinicians should aim to minimise risk by monitoring cardiovascular risk markers regularly in their patients and encouraging healthy lifestyle modifications. |
| Publish Date |
2020-02-28 10:31 |
| Citation |
Spanos C, Bretherton I, Zajac JD, Cheung AS. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review. World J Diabetes 2020; 11(3): 66-77 |
| URL |
https://www.wjgnet.com/1948-9358/full/v11/i3/66.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v11.i3.66 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
